Effectiveness of liraglutide in type II diabetes mellitus management: Experience in Emirati patients

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 8, Issue , 2015, Pages 67-72

  Ghuman, Nasrullah K ^a   Saadah, Loai M ^a   Al Najjar, Majdi S ^a   Shaheen, Duha Y ^a   Am, Shady I ^a   Al Ali, Mouza M ^a  

^a ZAYED MILITARY HOSPITAL   (United Arab Emirates)

Author keywords

Diabetes mellitus; Emirati; Liraglutide; Type II

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; SULFONYLUREA;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE INCREASE; DRUG EFFICACY; EMIRATI; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PRESCRIPTION; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SEX RATIO; SYSTOLIC BLOOD PRESSURE;

EID: 84942809131     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S31756     Document Type: Article

References (27)

1. Nauck M, Frid A, Hermansen K, Lead-2 Study Group. Efficacy and safety comparison of liraglutide, glimperide, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84-90.
2. Fadini GP, Simioni N, Frison V, et al. Independent glucose and weight-reducing effect of liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol. 2013;50(6):943-949.
3. Inoue K, Maeda N, Fujishima Y, et al. Long-term impact of liraglutide, glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. DiabetolMetab Syndr. 2014;6(1):95-103.
4. International Diabetes Federation World Atlas. 6th ed; 2013. Available at: http://www.idf.org/diabetesatlas/download-book. Accessed October 23, 2014.
5. Stone NJ, Robinson J, Liechtenstein HA, American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45.
6. Qaseem A, Fihn SD, Williams S, Clinical Guidelines Committee of the American College of Physicians. Diagnosis of stable ischmic heart disease: summary of a clinical practice guideline from the American College of Physicians/American Gollege of Caridology Foundation/American Heart Association/American Assosciatin for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med. 2012;157(10):729-734.
7. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(1):1-266.
8. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850-886.
9. Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009; 374:1606-1616.
10. Astrup A, Carraro R, Finer N, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2011;36:843-854.
11. Lane W, Weinrib S, Rappaport J, Hale C. The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial. Diabetes ObesMetab. 2014;16(9):827-832.
12. Gough SC, Bode B, Woo V, NN9068-3697 (DUAL-I) Trial Investigators. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocinoi. 2014;2(11):885-893.
13. Haraguchi A, Fujishima K, Ando T, et al. Multiple drug combination of antidiabetic agents as predictor of poor clinical response to liraglutide. Minerva Endocrinol. 2014;39(4):289-297.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications with type 2 diabetes. Lancet. 1998;352:837-853.
15. Maple-Brown LJ, Ye C, Retnakaran R. Area-under-the-HbA1c-curve above the normal range and the prediction of microvascular outcomes: an analysis of data from the diabetes control and complications trial. Diabet Med. 2013;30(1):95-99.
16. Nauck MA, Hompesch M, Filipczak R, NN2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Ciin Endo- crinoi Diabetes. 2006;114(8):417-423.
17. Niswender K, Pi-Sunyer X, Buse J, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013;15(1):42-54.
18. Jendle J, Nauck MA, Matthews DR, LEAD-2 and LEAD-3 Study Groups. Weight-loss with-liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12): 1163-1172.
19. Jensterle Sever M, Kocjan T, Pfeifer M, Kravos NA, Janez A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2014;170(3):451-459.
20. Potts JE, Gray LJ, Brady EM, Khunti K, Davies MJ, Bodicoat DH. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PLoS One. 2015;10(6):e0126769.
21. Rizzo M, Nikolic D, Banach M, Patti AM, Montalto G, Rizvi AA. Incretin-based therapies, glucometabolic health and endovascular inflammation. Curr Pharm Des. 2014;20(31):4953-4960.
22. Rizzo M, Chandalia M, Patti AM, et al. Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. Cardiovasc Diabetol. 2014;22(13):49.
23. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes ObesMetab. 2013;15(8):737-749.
24. Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014;28(3):399-405.
25. Jeyaraj S, Shetty AS, Kumar CR, et al. Liraglutide-induced acute pancreatitis. J Assoc Physicains India. 2014;62(1):64-66.
26. Chamler T, Almdal TP, Vilsboll T, Knop FK. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes-focus on pancreatitis and pancreas cancer. Expert Opin Drug Saf. 2014;3:1-10.
27. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Ailment Pharmacol Ther. 2013;37(2): 234-242.